Stable Angina, Unstable Angina, NSTEMINCT06183294
Evaluation of a Novel Non-Invasive Automated Fractional Flow Reserve Software System in Patients With Coronary Artery Disease
An observational study of Stable Angina, Unstable Angina, NSTEMI, run by University of California, San Diego at 1 site in United States.
Trial summary
This retrospective study will evaluate the coronary angiograms of approximately 100 patients who have undergone invasive angiography and fractional flow reserve (FFR). DICOM files of the angiograms will be analyzed on a secure computer within the cardiac catheterization laboratory using the AutocathFFR software to… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stable Angina, Unstable Angina, NSTEMI
- What is being tested?
- Collecting invasive FFR measurements.
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- 22 Aug 2023to 4 Jan 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Retrospective analysis of coronary angiograms of 100 consecutive patients who have undergone fractional flow reserve (FFR) testing within our institution
Who may be able to join
- patients who are >18 years of age, undergone a coronary angiogram for a clinically indicated reason, and who underwent coronary hemodynamic testing with invasive FFR.
Who cannot join
- Invasive FFR not obtained
Trial locations and contacts
1 site in 1 country.
About this study
This retrospective study will evaluate the coronary angiograms of approximately 100 patients who have undergone invasive angiography and fractional flow reserve (FFR). DICOM files of the angiograms will be analyzed on a secure computer within the cardiac catheterization laboratory using the AutocathFFR software to assess if invasive FFR measurements and automated computer analysis of FFR measurements correlate. AutocathFFR measurement per lesion will be compared to the gold standard, invasive FFR value, where an FFR ≤ 0.80 will be considered "positive", while an FFR > 0.8 will be considered "negative". The AutocathFFR value will be compared to the invasive FFR measurements. The sensitivity and specificity of the AutocathFFR will be calculated, as well as the AutocathFFR accuracy, positive predictive value and negative predictive value per lesion. Device success will be calculated as the ratio of completed versus initiated AutocathFFR index calculations. Usability of the AutocathFFR software will be evaluated using dedicated questionnaires to be completed by the user (cardiologists).
Read the detailed description
Coronary angiography is the gold standard for assessment of coronary artery disease. Coronary artery stenosis in lesions in the mild and severe range are easily interpreted by clinicians as meeting thresholds for clinical and hemodynamic significance. Moderate coronary artery disease remains an area of investigation and assessment as lesions in the 50-70% range are often unclear in their hemodynamic and clinical significance. Indices of coronary perfusion such as fractional flow reserve (FFR) have been developed to assess whether lesions are hemodynamically significant and could potentially benefit from revascularization. Assessment of FFR however requires further invasive testing, manipulation, and equipment, each with risk to the patient. We aim to retrospectively assess a non-invasive FFR software, the AutocathFFR system in the evaluation of coronary artery disease in patients who underwent invasive measurements to assess the accuracy of this system.
This study will assess the performance (sensitivity, specificity, accuracy) of the AutocathFFR measurements obtained from angiograms for the non-invasive determination of the presence of hemodynamically significant coronary lesions. The software device will be run on angiograms generated during cardiac catheterization and will be compared to the gold standard, invasive fractional flow reserve (FFR) measurements.Invasive coronary angiography (ICA) has long been considered the reference standard technique for the diagnosis of coronary artery disease (CAD). Decisions regarding revascularization procedures have traditionally been based on the visual assessment of coronary stenosis severity. However, this strategy is being challenged based on increasing recognition of the limitations of visual interpretation of conventional angiographic images. One of the major concerns is considerable inter-observer variability in interpretation of coronary angiograms1. Even the use of quantitative techniques has not substantially improved the predictive value of ICA for identifying the presence of lesion-specific ischemia2. Even more importantly, it is now recognized that many additional factors may collectively influence flow dynamics in a vessel in addition to the degree of narrowing at any single point. Accordingly, current evidence and guidelines stipulate that the decision to proceed to revascularization should be governed by the hemodynamic significance of a lesion, rather than angiographic severity alone, particularly for borderline ("gray zone") lesions. Currently, measurement of Fractional Flow Reserve (FFR) is the preferred technique for invasive assessment of flow limitation.
Fractional Flow Reserve, or FFR, is a measure usually gauged by an invasive wire that can accurately measure blood pressure in a specific part of the coronary artery. The wire is inserted through a standard diagnostic catheter at the time of a coronary angiogram and measurements obtained during hyperemic stimulus, typically with the use of intravenous or intracoronary adenosine.
An FFR value equal or less than 0.8 is generally considered to be the best discriminator of flow obstruction and the most relevant predictor of improved clinical outcome after coronary revascularization3,4. Trials such as Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention (FAME) 5,6, whereas those without ischemia receive little benefit, or even harm, with revascularization. Further, the Deferral Versus Performance of Percutaneous Coronary Intervention of Non-Ischemia-Producing Stenoses, (DEFER) trial has shown that patients with non-flow-limiting lesions do not require intervention and show favorable outcomes with use of optimal medical therapy alone, with annual rates of myocardial infarction and mortality of less than 1%7. Accordingly, evaluation of the hemodynamic significance of coronary stenosis during ICA by using pressure wire-derived FFR, an approach that allows combined anatomic and physiologic assessment, has become a cornerstone to determine lesion-specific ischemia and appropriate decision making8,9. Furthermore based on the above studies, the American (ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/ STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients with Stable Ischemic Heart Disease10) and European (ESC/EACTS Guidelines on myocardial revascularization11) Guidelines recommend the routine use of FFR for further defining the need for revascularization.
Nevertheless, there are several risks associated with invasive FFR, including the use of an invasive pressure wire through the coronary arteries, drift in the pressure wire reading, side effects from hyperemic agents, the additional time required to perform the procedure in multiple blood vessels, as well as other technical challenges associated with the procedure. For these reasons, as well as others, such as costs and time, invasive FFR is not employed in many procedures even though it may provide clinically useful information.
As physiology-guided revascularization is important as pointed out by the American and European Guidelines, non-invasive techniques for measuring FFR have been developed. The ability to simulate the value measured by invasive FFR devices by computer models has been demonstrated by several devices.
- Conditions
- Stable Angina, Unstable Angina, NSTEMI
- Being tested
- Collecting invasive FFR measurements.
- Medical subject headings
- Angina, Stable, Angina, Unstable, Non-ST Elevated Myocardial Infarction
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collecting invasive FFR measurements.Other
Also called Data collection
Invasive FFR measurements from the patient's hospital records will be collected.
| Study group | Role | What they receive |
|---|---|---|
| : adult subjects who underwent a clinically indicated invasive coronary angiography | adult subjects with stable angina, unstable angina or NSTEM1 who underwent a clinically indicated invasive coronary angiography and on whom invasive FFR has been measured in vessels with coronary lesions.
Interventions:
Other: Collecting invasive FFR measurements. Receives: Other: Collecting invasive FFR measurements. |
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess the performance (sensitivity, specificity, accuracy) of the AutocathFFR measurements obtained from angiograms for the non-invasive determination of the presence of hemodynamically significant coronary lesions.
The software device will be run on angiograms generated during cardiac catheterization and will be compared to the gold standard, invasive fractional flow reserve (FFR) measurements.
Measured: 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Dec 2023
- Study start22 Aug 2023
- Primary completion4 Jan 2024
- Study completion4 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Stable Angina, Unstable Angina, NSTEMIStudies of the same condition, open and under way.
- More trials run by University of California, San DiegoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, San Diego
- Sponsor type
- University, hospital or other
- Collaborators
- MedHub-AI
- Responsible party
- Principal investigator, Ehtisham Mahmud, University of California, San Diego
- Investigators
- Ehtisham Mahmud, MD, Principal investigator, UC San Diego Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06183294
- Sponsor's protocol ID
- 808066
- Status last verified
- Nov 2025
- First submitted
- 13 Dec 2023
- Last updated
- 6 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of a Novel Non-Invasive Automated Fractional Flow Reserve Software System in Patients With Coronary Artery Disease
- ClinicalTrials.gov ID
- NCT06183294
- Acronym / sponsor ID
- 808066
- Conditions
- Stable Angina, Unstable Angina, NSTEMI
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- University of California, San DiegoUniversity, hospital or other
- Collaborators
- MedHub-AI
- Study start
- 22 Aug 2023 (actual)
- Primary completion
- 4 Jan 2024 (actual)
- Study completion
- 4 Jan 2024 (actual)
- First posted
- 27 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective study will evaluate the coronary angiograms of approximately 100 patients who have undergone invasive angiography and fractional flow reserve (FFR). DICOM files of the angiograms will be analyzed on a secure computer within the cardiac catheterization laboratory using the AutocathFFR software to assess if invasive FFR measurements and automated computer analysis of FFR measurements correlate. AutocathFFR measurement per lesion will be compared to the gold standard, invasive FFR value, where an FFR ≤ 0.80 will be considered "positive", while an FFR > 0.8 will be considered "negative". The AutocathFFR value will be compared to the invasive FFR measurements. The sensitivity and specificity of the AutocathFFR will be calculated, as well as the AutocathFFR accuracy, positive predictive value and negative predictive value per lesion. Device success will be calculated as the ratio of completed versus initiated AutocathFFR index calculations. Usability of the AutocathFFR software will be evaluated using dedicated questionnaires to be completed by the user (cardiologists).
Detailed description
Coronary angiography is the gold standard for assessment of coronary artery disease. Coronary artery stenosis in lesions in the mild and severe range are easily interpreted by clinicians as meeting thresholds for clinical and hemodynamic significance. Moderate coronary artery disease remains an area of investigation and assessment as lesions in the 50-70% range are often unclear in their hemodynamic and clinical significance. Indices of coronary perfusion such as fractional flow reserve (FFR) have been developed to assess whether lesions are hemodynamically significant and could potentially benefit from revascularization. Assessment of FFR however requires further invasive testing, manipulation, and equipment, each with risk to the patient. We aim to retrospectively assess a non-invasive FFR software, the AutocathFFR system in the evaluation of coronary artery disease in patients who underwent invasive measurements to assess the accuracy of this system.
This study will assess the performance (sensitivity, specificity, accuracy) of the AutocathFFR measurements obtained from angiograms for the non-invasive determination of the presence of hemodynamically significant coronary lesions. The software device will be run on angiograms generated during cardiac catheterization and will be compared to the gold standard, invasive fractional flow reserve (FFR) measurements.Invasive coronary angiography (ICA) has long been considered the reference standard technique for the diagnosis of coronary artery disease (CAD). Decisions regarding revascularization procedures have traditionally been based on the visual assessment of coronary stenosis severity. However, this strategy is being challenged based on increasing recognition of the limitations of visual interpretation of conventional angiographic images. One of the major concerns is considerable inter-observer variability in interpretation of coronary angiograms1. Even the use of quantitative techniques has not substantially improved the predictive value of ICA for identifying the presence of lesion-specific ischemia2. Even more importantly, it is now recognized that many additional factors may collectively influence flow dynamics in a vessel in addition to the degree of narrowing at any single point. Accordingly, current evidence and guidelines stipulate that the decision to proceed to revascularization should be governed by the hemodynamic significance of a lesion, rather than angiographic severity alone, particularly for borderline ("gray zone") lesions. Currently, measurement of Fractional Flow Reserve (FFR) is the preferred technique for invasive assessment of flow limitation.
Fractional Flow Reserve, or FFR, is a measure usually gauged by an invasive wire that can accurately measure blood pressure in a specific part of the coronary artery. The wire is inserted through a standard diagnostic catheter at the time of a coronary angiogram and measurements obtained during hyperemic stimulus, typically with the use of intravenous or intracoronary adenosine.
An FFR value equal or less than 0.8 is generally considered to be the best discriminator of flow obstruction and the most relevant predictor of improved clinical outcome after coronary revascularization3,4. Trials such as Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention (FAME) 5,6, whereas those without ischemia receive little benefit, or even harm, with revascularization. Further, the Deferral Versus Performance of Percutaneous Coronary Intervention of Non-Ischemia-Producing Stenoses, (DEFER) trial has shown that patients with non-flow-limiting lesions do not require intervention and show favorable outcomes with use of optimal medical therapy alone, with annual rates of myocardial infarction and mortality of less than 1%7. Accordingly, evaluation of the hemodynamic significance of coronary stenosis during ICA by using pressure wire-derived FFR, an approach that allows combined anatomic and physiologic assessment, has become a cornerstone to determine lesion-specific ischemia and appropriate decision making8,9. Furthermore based on the above studies, the American (ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/ STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients with Stable Ischemic Heart Disease10) and European (ESC/EACTS Guidelines on myocardial revascularization11) Guidelines recommend the routine use of FFR for further defining the need for revascularization.
Nevertheless, there are several risks associated with invasive FFR, including the use of an invasive pressure wire through the coronary arteries, drift in the pressure wire reading, side effects from hyperemic agents, the additional time required to perform the procedure in multiple blood vessels, as well as other technical challenges associated with the procedure. For these reasons, as well as others, such as costs and time, invasive FFR is not employed in many procedures even though it may provide clinically useful information.
As physiology-guided revascularization is important as pointed out by the American and European Guidelines, non-invasive techniques for measuring FFR have been developed. The ability to simulate the value measured by invasive FFR devices by computer models has been demonstrated by several devices.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| : adult subjects who underwent a clinically indicated invasive coronary angiography | – | Other: Collecting invasive FFR measurements.adult subjects with stable angina, unstable angina or NSTEM1 who underwent a clinically indicated invasive coronary angiography and on whom invasive FFR has been measured in vessels with coronary lesions. Interventions: Other: Collecting invasive FFR measurements. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Retrospective analysis of coronary angiograms of 100 consecutive patients who have undergone fractional flow reserve (FFR) testing within our institution
Key inclusion criteria (1 listed)
- patients who are >18 years of age, undergone a coronary angiogram for a clinically indicated reason, and who underwent coronary hemodynamic testing with invasive FFR.
Key exclusion criteria (1 listed)
- Invasive FFR not obtained
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collecting invasive FFR measurements.Also: Data collectionInvasive FFR measurements from the patient's hospital records will be collected. | Other | : adult subjects who underwent a clinically indicated invasive coronary angiography |
Primary outcome
To assess the performance (sensitivity, specificity, accuracy) of the AutocathFFR measurements obtained from angiograms for the non-invasive determination of the presence of hemodynamically significant coronary lesions.
Time frame: 2 months
The software device will be run on angiograms generated during cardiac catheterization and will be compared to the gold standard, invasive fractional flow reserve (FFR) measurements.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Stable Angina, Unstable Angina, NSTEMI
RecruitingObservational study
Safety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery Disease
Coronary Arterial Disease (CAD), NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)
Recruiting
Advanced NanoTherapies Dual-API DCB to Treat De-Novo and ISR Lesions in Patients With Symptomatic Coronary Artery Disease
Angina (Stable), CAD - Coronary Artery Disease
Recruiting
Breaking Fasts Ahead of Cardiac Caths
Stable Angina (SA), Unstable Angina (UA)
Active, not recruiting
Advanced NanoTherapies Dual-API DCB to Treat De-Novo Lesions in Patients With Symptomatic Coronary Artery Disease
Coronary Artery Disease
Recruiting
PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlusions
Multi Vessel Coronary Artery Disease, Non-ST Elevation Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ehtisham Mahmud, MD principal investigator
UC San Diego Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stable Angina, Unstable Angina, NSTEMI, run by University of California, San Diego at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess the performance (sensitivity, specificity, accuracy) of the AutocathFFR measurements obtained from angiograms for the non-invasive determination of the presence of hemodynamically significant coronary lesions. (time frame: 2 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2025.